Axalimogene filolisbac: Ph III AIM2CERV started

Advaxis began the double-blind, placebo-controlled, international Phase III AIM2CERV trial to evaluate axalimogene filolisbac as adjuvant therapy following concurrent chemotherapy and radiation treatm...